Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:50905 |
Name | inflammatory myofibroblastic tumor |
Definition | A mesenchymal cell neoplasm that has_material_basis_in myofibroblastic cells admixed with inflammatory cells. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer cell type cancer mesenchymal cell neoplasm inflammatory myofibroblastic tumor |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
ALK fusion | Crizotinib | inflammatory myofibroblastic tumor | sensitive | detail... |
EML4 - ALK | Crizotinib | inflammatory myofibroblastic tumor | predicted - sensitive | detail... |
ALK rearrange | Ceritinib | inflammatory myofibroblastic tumor | sensitive | detail... |
ALK rearrange | Crizotinib | inflammatory myofibroblastic tumor | sensitive | detail... |
ALK rearrange | Brigatinib | inflammatory myofibroblastic tumor | sensitive | detail... |
ALK rearrange | Lorlatinib | inflammatory myofibroblastic tumor | sensitive | detail... |
EML4 - ALK | Alectinib | inflammatory myofibroblastic tumor | predicted - sensitive | detail... |
ALK rearrange | Alectinib | inflammatory myofibroblastic tumor | sensitive | detail... |
ALK positive | Alectinib | inflammatory myofibroblastic tumor | predicted - sensitive | detail... |
EML4 - ALK ALK I1171N | Alectinib | inflammatory myofibroblastic tumor | predicted - resistant | detail... |
EML4 - ALK ALK I1171N | Lorlatinib | inflammatory myofibroblastic tumor | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04741438 | Phase III | Ipilimumab + Nivolumab Pazopanib | Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype (RAR-Immune) | Recruiting | FRA | 0 |
NCT04925609 | Phase Ib/II | Brigatinib | Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors (Briga-PED) | Recruiting | NLD | FRA | 0 |